The European Medicines Agency has approved the use of Velcade -- a drug developed by Millennium Pharmaceuticals and Johnson & Johnson -- as first-line treatment combined with melphalan and prednisone for patients with multiple myeloma. The clearance provides a new option for myeloma patients not eligible to undergo high-dose chemotherapy and bone marrow transplants.

Related Summaries